Search results
Results from the Tech24 Deals Content Network
Friday, Bristol Myers Squibb & Co (NYSE:BMY) posted second-quarter revenues of $12.20 billion, beating the consensus of $11.55 billion, an increase of 9% year-over-year, or 11% when adjusted for ...
Bristol Myers Squibb stock tanked in April after management lowered the midpoint of its earnings outlook for 2024 from $7.25 per share to just $0.55 to account for a $12.1 billion IPRD charge ...
Bristol Myers Squibb: A high-yield dividend stock with an attractive valuation. Bristol Myers Squibb, or BMS for short, is another well-established pharmaceutical company with a strong presence in ...
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb ( BMS ), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, [ 2] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
Bristol Myers said it earned $1.75 per share in the quarter, well below analyst expectations of $1.96. It cut its 2023 earnings forecast by 60 cents to a range of $7.35 to $7.65 a share.
A plan offered in November 2009 would allow shareholders of Bristol-Myers to exchange one dollar of stock in that company for $1.11 worth of shares in Mead Johnson for the 133.5 million shares in the firm, which would value the company at $7.7 billion based on the stock's then current closing price.
By Michael Erman. (Reuters) -Drugmaker Bristol Myers Squibb on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new ...
Bristol-Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.59% move from the prior day.